Improving the detection of patients with inherited predispositions to hematologic malignancies using next‐generation sequencing‐based leukemia prognostication panels
Abstract
Recognizing and referring patients with possible inherited cancer predisposition syndromes for appropriate genetic evaluation and testing provides insights into optimal patient treatment approaches and also can provide education and testing opportunities for family members. Next‐generation sequencing (NGS)‐based, targeted genotyping for somatic mutations is increasingly used in the diagnosis, prognostication, and treatment selection for patients with hematologic malignancies. However, certain mutations that may be somatically acquired can also be present as germline mutations in some individuals and families. Whether the results of NGS‐based leukemia panels can be used to inform decisions and subsequent evaluation of patients with possible inherited cancer predispositions has not been described previously. Because a normal control often is not available when using NGS panels in patients with hematologic malignancies, NGS panel results offer both an opportunity and a challenge to determine the origin and pathogenicity of identified mutations. In the absence of a matched germline control, variant allele frequency (VAF) estimation and data from publically available data sets provide important clues to the possible germline origin of a variant. Careful annotation and review of NGS panels in patients with hematologic malignancies can provide a useful screening tool to systematically improve upon the detection of potentially pathogenic germline variants. Cancer 2018;124:2704‐2713. © 2018 American Cancer SocietyKeywords
Funding Information
- The University of Texas MD Anderson Cancer Center Support (CA016672)
- Charif Souki Cancer Research Fund
- University of Texas MD Anderson Cancer Center Leukemia Specialized Program of Research Excellence (CA100632)
This publication has 45 references indexed in Scilit:
- Proposal for the clinical detection and management of patients and their family members with familial myelodysplastic syndrome/acute leukemia predisposition syndromesLeukemia & Lymphoma, 2012
- Familial myelodysplastic syndromes: a review of the literatureHaematologica, 2011
- Mutations in the 5′ UTR of ANKRD26, the Ankirin Repeat Domain 26 Gene, Cause an Autosomal-Dominant Form of Inherited Thrombocytopenia, THC2The American Journal of Human Genetics, 2011
- Population prevalence of familial cancer and common hereditary cancer syndromes. The 2005 California Health Interview SurveyGenetics in Medicine, 2010
- SNP array analysis in hematologic malignancies: avoiding false discoveriesBlood, 2010
- Somatic CEBPA Mutations Are a Frequent Second Event in Families With Germline CEBPA Mutations and Familial Acute Myeloid LeukemiaJournal of Clinical Oncology, 2008
- Cancer risks in Fanconi anemia: findings from the German Fanconi Anemia RegistryHaematologica, 2008
- Diagnosis, Genetics, and Management of Inherited Bone Marrow Failure SyndromesHematology-American Society Hematology Education Program, 2007
- Hereditary Cancer Predisposition SyndromesJournal of Clinical Oncology, 2005
- Mutation ofCEBPAin Familial Acute Myeloid LeukemiaNew England Journal of Medicine, 2004